Elisabeth G E de Vries
Overview
Explore the profile of Elisabeth G E de Vries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
394
Citations
12806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tannock I, de Vries E, Fojo A, Buyse M, Moja L
Lancet Oncol
. 2025 Mar;
26(3):e171-e180.
PMID: 40049207
Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have been shown...
2.
van Geel J, Moustaquim J, Boers J, Elias S, Smeets E, Knip J, et al.
J Nucl Med
. 2025 Jan;
66(2):194-200.
PMID: 39848768
Intrapatient heterogeneity of estrogen receptor (ER) expression on 16α-[F]fluoro-17β-estradiol ([F]FES) PET is related to outcome in patients with ER-positive metastatic breast cancer (MBC), but a validated and practical method to...
3.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, et al.
Clin Cancer Res
. 2024 Oct;
31(1):110-121.
PMID: 39470686
Purpose: The ZEPHIR clinical trial evaluated the role of [89Zr]trastuzumab-PET/CT (HER2-PET/CT) and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT ([18F]FDG-PET/CT) in predicting outcomes in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1)....
4.
Colombo R, Tarantino P, Rich J, LoRusso P, de Vries E
Cancer Discov
. 2024 Oct;
14(11):2089-2108.
PMID: 39439290
Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical...
5.
van Winkel C, Pierik F, Brouwers A, de Groot D, de Vries E, Lub-de Hooge M
Nat Rev Clin Oncol
. 2024 Sep;
21(12):852-866.
PMID: 39327536
Multispecific antibodies are engineered antibody derivatives that can bind to two or more distinct epitopes or antigens. Unlike mixtures of monospecific antibodies, the binding properties of multispecific antibodies enable two...
6.
de Groot D, Lub-de Hooge M, van Meerten T, Brouwers A, de Vries E
Clin Cancer Res
. 2024 Sep;
30(23):5252-5259.
PMID: 39325013
Current immunotherapies have brought major progress in cancer treatments, but not all patients benefit. Therefore, insight into reasons for treatment failure and optimal biomarkers for patient selection are warranted. Current...
7.
Wyatt A, Litiere S, Bidard F, Cabel L, Dyrskjot L, Karlovich C, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5034-5041.
PMID: 39269996
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in...
8.
Gangaev A, van Sleen Y, Brandhorst N, Hoefakker K, Prajapati B, Singh A, et al.
Front Immunol
. 2024 Sep;
15:1447555.
PMID: 39257577
Introduction: Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains...
9.
Eisses B, van Geel J, Brouwers A, Bensch F, Elias S, Kuip E, et al.
J Nucl Med
. 2024 Sep;
65(10):1540-1547.
PMID: 39237347
Understanding which patients with human epidermal growth factor receptor 2 (HER2)-negative or -low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is urgently needed. We assessed the whole-body heterogeneity of...
10.
Broer L, Knapen D, de Groot D, Mol P, Kosterink J, de Vries E, et al.
iScience
. 2024 Jul;
27(6):110115.
PMID: 38974466
Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies. Their high prices burden healthcare...